Lifetime Impact of Achondroplasia Study in Europe-LIAISE

Achondroplasia Clinical Trial

— LIAISE  

Official title:

The Impact of Achondroplasia on Quality of Life, Healthcare Resource Use, Clinical, Socio-economic and Psychosocial State of the Individual.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03449368
• Other study ID #: 111-501
• Status: Completed
• Start date: December 17, 2017
• Est. completion date: April 29, 2020

Study information

• Verified date: February 2020
• Source: BioMarin Pharmaceutical
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Observational study looking at the burden of illness in achondroplasia subjects aged 5-70. The study will include a 5 year review of historical clinical data as well as a single point collection of questionnaire data to look at the impact on the following in individuals with achondroplasia versus a normative population: - Quality of life - Clinical burden - Healthcare resource use - Socio-economic burden - Psychosocial burden Up to 300 subjects will be included in sites in Germany, Spain, Italy, Sweden, Austria and Denmark

Description:

This is a multinational, epidemiological, observational, retrospective, cross-sectional study of individuals with achondroplasia (subjects). This study will be conducted at up to approximately 20 sites in European countries. Subjects will be invited to enroll via 3 routes: 1. During routine hospital visits 2. From subject lists of those previously treated but no longer followed at the study site. 3. Through collaboration of the Investigator with achondroplasia patient organizations, other achondroplasia-related organizations, other healthcare professionals in their country and achondroplasia-related social media sites. A recruitment flyer will be provided to these organizations, healthcare professionals and social media sites and will to be distributed to potential subjects. Data will be collected over a minimum of the five years prior to the date of enrolment. Clinical and healthcare resource use data will be collected from medical records. For each subject enrolled, data from medical records will be collected and entered onto an electronic case report form (eCRF) at each site. Data collection from medical records will be supplemented by records provided by the subject and, if necessary, confirmed by the family doctor. Data about QoL, psychosocial burden, socioeconomic burden and healthcare resource use will be collected via a booklet of validated and structured questionnaires. Characteristics of subjects with achondroplasia (QoL scores, healthcare resource use, educational level, family status, employment status) will be compared with those of the general population, where available. As this is an observational study, participation will not affect the subject/Investigator relationship, nor influence Investigator's treatment, therapeutic or other management of the subject.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 196
• Est. completion date: April 29, 2020
• Est. primary completion date: April 29, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Individuals with a documented diagnosis of achondroplasia based on:

1. Genetic confirmation of achondroplasia and/or

2. Clinical diagnosis of achondroplasia (clinical examination or radiological assessment)

2. = five years of age at the time of enrolment

3. Has the cognitive and linguistic capacities necessary to complete questionnaires in the language of his/her country (and/or parents/legally acceptable representatives, as applicable)

4. Agrees to participate in the study and has read, understood, completed and signed:

1. Informed Consent Form (ICF) - for adult subjects

2. Informed Assent Form (IAF) - for minor subjects, accompanied by a parental ICF completed by their parents/legally acceptable representatives. The age at which the minor subjects sign the IAF will be subject to local requirements.

5. Has medical records available for at least the five years prior to the date of enrolment.

Exclusion Criteria:

1. Currently participating, or participated within the last six months, in

1. a clinical trial of a medicinal product or medical device or,

2. other non-clinical, low interventional studies

2. Currently participating or participated in any BioMarin study at any time.

Related Conditions & MeSH terms

• Achondroplasia

Locations

Country	Name	City	State
Austria	Medizinische Universitat Wien	Vienna
Denmark	Aarhus Universitetshospital	Aarhus
Germany	Klinik für Kinder- und Jugendmedizin	Cologne
Germany	Medizinische Fakultät, Universitätskinderklinik (KPAE)	Magdeburg
Germany	Universitätsmedizin	Mainz
Italy	UOC Pediatria	Como
Italy	Maternal and Child Health - University of Genova	Genova
Italy	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Roma
Spain	Hospital Universitario La Paz	Madrid
Spain	Se ubica en los siguientes centros, Hospital Universitario Virgen de la Victoria	Málaga
Spain	Hospital Clínico Universitario Virgen de la Arrixaca	Murcia
Spain	Unidad de Dismorfología y metabolismo Hospital Universitario Virgen del Rocío	Sevilla
Sweden	Karolinska Hospital	Solna

Sponsors (1)

Lead Sponsor	Collaborator
BioMarin Pharmaceutical

Countries where clinical trial is conducted

Austria,  Denmark,  Germany,  Italy,  Spain,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Measurement of Height	Height measurements will be collected from retrospective data where available for standing and sitting height measurements. The height data will be measured in centimetres.	Retrospective data will be collected for 5 years prior to date of enrolment
Other	Measurement of Weight Body Mass Index	Weight will be collected from retrospective data collected and will be entered in kilograms.	Retrospective data will be collected for 5 years prior to date of enrolment
Other	Body Mass Index (BMI)	Body Mass Index is calculated using height and weight. Body Mass Index (BMI) will be measured in kg/m2	Retrospective data will be collected for 5 years prior to date of enrolment
Primary	Healthcare resource use	Healthcare resource use will be collected from medical records and through patient questionnaires. Data collection from medical records will be supplemented by records provided by the subject and, if necessary, confirmed by the family doctor. Healthcare resource use will be collected via a booklet of validated and structured questionnaires	Once at start of study per subject through completion of questionnaires and via retrospective review of historical data. These will be assessed at interim analysis November 2018 and again at end of study with final Clinical Study Report March 2020
Secondary	Socio-economic burden (educational, personal, employment and financial impact)	Data about socio-economic burden will be collected via a booklet of validated and structured questionnaires specifically the Work and Productivity and Activity Impairment (WPAI-SHP)	Outcomes will be collected once at start of study per subject through completion of questionnaires. These will be assessed at interim analysis November 2018 and again at end of study with final Clinical Study Report March 2020
Secondary	Pediatric Functional Independence Measure (WeeFIM)	The WeeFIM measures the need for assistance and the severity of disability in children between six months and seven years of age. The instrument consists of 18 items covering three domains: self-care, mobility, and cognition. The mean total score within each domain and the overall total score will be summarized.	Data will be collected once at start of study per subject through completion of questionnaires. These will be assessed at interim analysis November 2018 and again at end of study with final Clinical Study Report March 2020
Secondary	Adolescent Pediatric Pain Tool (APPT)	The APPT is an instrument for self-reporting of pain by children and adolescents aged 8-17 years. Five subscale scores will be summarized on the analysis population	Data will be collected once at start of study per subject through completion of questionnaires. These will be assessed at interim analysis November 2018 and again at end of study with final Clinical Study Report March 2020
Secondary	Pediatric Quality of Life Inventory (PedsQL)	The PedsQL is comprised of four dimensions: Physical, Emotional, Social, and School Functioning. The overall score for each dimension is defined as the mean score for each item involved in the dimension. The overall score for each dimension and the mean total score across dimensions will be summarized for each report.	Data will be collected once at start of study per subject through completion of questionnaires. These will be assessed at interim analysis November 2018 and again at end of study with final Clinical Study Report March 2020
Secondary	Quality of Life Short Stature Youth (QoLiSSY) Questionnaire	The QoLISSY Questionnaire for children and adolescents consists of the core QOL dimensions: Physical, Social and Emotional, and three predictors of quality of life: Coping, Beliefs and Treatment. The QoLISSY total score is calculated by the sum of the means in the physical, social and emotional sub-scales divided by 3.	Data will be collected once at start of study per subject through completion of questionnaires. These will be assessed at interim analysis November 2018 and again at end of study with final Clinical Study Report March 2020
Secondary	Nottingham Health Profile(NHP) Questionnaire	The NHP is a generic quality of life survey used to measure subjective physical, emotional, and social aspects of health. The NHP total score is calculated by averaging the six domain scores.	Data will be collected once at start of study per subject through completion of questionnaires. These will be assessed at interim analysis November 2018 and again at end of study with final Clinical Study Report March 2020
Secondary	Brief Pain Inventory-Short Form (BPI-SF) Questionnaire	The BPI-SF is used to assess clinical pain. A mean severity score and mean interference score will be calculated and summarized for the analysis population	Data will be collected once at start of study per subject through completion of questionnaires. These will be assessed at interim analysis November 2018 and again at end of study with final Clinical Study Report March 2020
Secondary	EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Questionnaire	EQ-5D-5L questionnaire has 5 dimensions: "Mobility", "Human Autonomy," "Current Activities", "Pain / Discomfort", "Anxiety / Depression" and all dimensions are described by 5 problem levels corresponding to patient response choices. A quality of life score is obtained according to the answers to the questionnaires.	Data will be collected once at start of study per subject through completion of questionnaires. These will be assessed at interim analysis November 2018 and again at end of study with final Clinical Study Report March 2020